Format

Send to

Choose Destination
See comment in PubMed Commons below
Chimerism. 2013 Jul-Sep;4(3):84-6. doi: 10.4161/chim.24718. Epub 2013 Sep 12.

A feasibility study on the prediction of acute graft-vs.-host disease before hematopoietic stem cell transplantation based on fetomaternal tolerance.

Author information

1
Department of Pediatrics and Cell Transplantation; Mie University Graduate School of Medicine; Edobashi, Japan.

Abstract

The contact between the immune systems of mother and child during pregnancy affects an immune response of the child against noninherited maternal antigens (NIMA) and the mother against inherited paternal antigens (IPA). However, the immunologic effects of developmental exposure to NIMA or IPA are heterogeneous, and can be either tolerogenic or immunogenic. Although we have reported that prediction of acute graft-vs.-host disease (GVHD) is feasible in a murine model, there has been no literature in human. We devised a novel method for predicting a tolerogenic effect by using mixed lymphocyte reaction combined with enzyme-linked immunospot (MLR-ELISPOT) assay. The assay can evaluate reactivity of interferon-γ spot-forming cells of donor against the recipient. Although we have shown only two examples of mother to child reactivity so far, our preliminary results suggest that this pre-screened assay may be used to predict acute GVHD. The clinical trial is in progress to evaluate MLR-ELISPOT assay as a predicting measure of acute GVHD in haploidentical transplantation from NIMA or IPA-mismatched family donor.

KEYWORDS:

MLR-ELISPOT; NIMA; acute GVHD; fetomaternal tolerance; hematopoietic stem cell transplantation

PMID:
23639967
PMCID:
PMC3782549
DOI:
10.4161/chim.24718
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center